Dr. Buckhaults detailed the difference between "Process One" (used for clinical trials) and "Process Two" (used for mass production). While the trial batches used clean PCR products, the production batches used bacteria-grown plasmid DNA to scale up, leading to the contamination. He urged the FDA to require Pfizer to "clean up" the vaccines, noting that different batches have varying levels of DNA, which may explain the inconsistency in adverse events.
